Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Sci Rep. 2022 Jan 7;12(1):271. doi: 10.1038/s41598-021-04397-z.
The current study was performed to evaluate the effects of alpha-lipoic acid (ALA) supplementation on lactate, nitric oxide (NO), vascular cell adhesion molecule-1 (VCAM-1) levels, and clinical symptoms in women with episodic migraines. Considering the inclusion and exclusion criteria, ninety-two women with episodic migraines participated in this randomized, double-blind, placebo-controlled, parallel-design trial. The participants were randomly assigned to receive either 300 mg/day ALA or placebo, twice per day for 12 weeks. The primary outcomes included headache severity, headache frequency per month, and duration of attacks and the secondary outcomes included lactate (a marker of mitochondrial function), NO, and VCAM-1 serum levels were measured at baseline and the end of the intervention. At the end of the study, there was a significant decrease in lactate serum levels (- 6.45 ± 0.82 mg/dl vs - 2.27 ± 1.17 mg/dl; P = 0.039) and VCAM-1 (- 2.02 ± 0.30 ng/ml vs - 1.21 ± 0.36 ng/ml; P = 0.025) in the ALA as compared to the placebo group. In addition, the severity (P < 0.001), frequency (P = 0.001), headache impact test (HIT-6) (P < 0.001), headache dairy results (HDR) (P = 0.003), and migraine headache index score (MHIS) (P < 0.001) had significantly decreased in the intervention as compared to the control group. No significant changes were observed for NO levels and duration of migraine pains. ALA supplementation can be considered a potential adjunct treatment in patients with migraine due to its improving mitochondrial and endothelial functions and clinical symptoms.
本研究旨在评估α-硫辛酸（ALA）补充剂对发作性偏头痛女性的乳酸、一氧化氮（NO）、血管细胞黏附分子-1（VCAM-1）水平和临床症状的影响。根据纳入和排除标准，92 名发作性偏头痛女性参与了这项随机、双盲、安慰剂对照、平行设计试验。参与者被随机分为每天接受 300mg ALA 或安慰剂，每天两次，共 12 周。主要结局包括头痛严重程度、每月头痛频率和发作持续时间，次要结局包括乳酸（线粒体功能标志物）、NO 和 VCAM-1 血清水平，在基线和干预结束时测量。研究结束时，与安慰剂组相比，ALA 组血清乳酸水平显著下降（-6.45±0.82mg/dl 与-2.27±1.17mg/dl；P=0.039），VCAM-1 水平也显著下降（-2.02±0.30ng/ml 与-1.21±0.36ng/ml；P=0.025）。此外，与对照组相比，ALA 组的头痛严重程度（P<0.001）、频率（P=0.001）、头痛影响测试（HIT-6）（P<0.001）、头痛日记结果（HDR）（P=0.003）和偏头痛头痛指数评分（MHIS）（P<0.001）均显著降低。NO 水平和偏头痛持续时间没有显著变化。ALA 补充剂可能被认为是偏头痛患者的一种潜在辅助治疗方法，因为它可以改善线粒体和内皮功能以及临床症状。
